Job Description

Pfizer’s industry-leading portfolio of anti-virals-is comprised of Paxlovid and ibuzatrelvir(“ibuza”).

This new leader will have the opportunity to concurrently focus on accelerating and reigniting the growth of an in-line brand, while also preparing for launch of a new asset. At launch in the 2021-2022 time-frame, there was tremendous anticipation and unmet need for PAXLOVID as the infection rates swelled.As the 1st-to-market oral protease inhibitor for the treatment SARS-CoV-2,Paxlovid rapidly seized dominant market share leadership, which still holds today It dwarfed revenue targets and was well on its way to becoming a household name. To date, it’s treated 3M+ patients worldwide. However, the COVID-19 epidemiology evolved following the emergence of the Omicron variant. The ensuing sub-variants were believed to have variable transmission rates, with lower pathogenicity and virulence, resulting in notably fewer hospitalizations and deaths. This marked the transition of COVID-19 from an epidemic to endemic.

The trend toward fewer and less potent cases was one reason for a sharpdrop in Paxlovid prescription volume. The Paxlovidslowdown was multifactorial. In addition to the epidemiology, the sharp decline in volume is being partially attributed to HCP inertia and patient apathy(springing from the perception of less severe disease and milder symptoms), as well as concerns over DDIs and dysgeusia (metallic taste) And, of course, the population at large was gaining immunity via COVID vaccinations and natural infections, which reduced the addressable patient population.In the aftermath of this raging public health crisis, a deep fatigue set in, particularly amongst HCPs and consumers All that said, agnostic to the trend in infections, our patient funnel modeling illuminate headroom for growthmid-funnel,specifically in “patient seeking care” behavior and “HCP treatment rate”.

Ibuzais being developed as a follow-on to Paxlovid, but does not contain ritonavir, whichprecipitated DDIs and the dysgeusiaDue to this favorable product profile,we’ll be evaluating not only the safety and the risk reduction of the composite death/hospital endpoint, but also the impact on symptom alleviation and prevention of post-acute sequelae of COVID. Ibuza’s Ph3 RCT is underway and is tracking to approval across markets in the 2029-2030 time frame. Interestingly, PAXLOVID has a long runway to LOE, which is slated for 2041.

Inshort, the incoming Senior Director/Global Team Leader for COVID-19 treatmentwill inherit a ~$3B revenue target for 2026, a competitiveOpEx budget, and six-to-seven direct reportsIn exchange, the new Leader is expected to embrace our franchise purpose to “ensure no eligible high-risk patients are left untreated” and to champion our ambition to further entrench our market leadership

This role provides an excellent opportunity to shape the commercial potential of both assets. In Global Marketing, we translate science into value for patients.  Our remit is to own the strategic direction across the asset lifecycle, ensure long-term value creation and preservation, and drive brand consistency across markets and efficiencies in execution.

This role will report to the Vice President, Global Franchise Lead for (non-obesity) IM, AV, and Migraine

ROLE RESPONSIBILITIES

• Recruit, grow, recognize, reward, empower, and promote the top Marketing talent from across Pfizer.

• Shape global commercial strategy and launch strategy, inclusive of brand co-positioning, messaging, and market development, in lock step with ICO, CSI, and US partners.

• Represent Global Commercial voice and point of view on various global governance teams for each asset, as theLead, Co-Lead or contributor, alongside CSI, Clinical Development, Regulatory, Global Access & Value, and Global Medical Affairs to ensure key opportunities and risks in the clinical development plan meet the target product profile and incorporate commercial insights from inline/launch experiences with Paxlovid

• Partner with CSI to drive thought leadership on the commercialization plan and lifecycle management prioritiesto ensure value creation for the mid-to-long term horizon

• Coach, enable, and collaborate with the ibuza Launch Lead and cross-functional partners to ensure launch readiness

• Ensure proactive translation of key competitive intelligence into action; and prepare senior leadership communications

• Make decisions that are in accordance with Company policies and SOPs, Pfizer Values & global regulatory guidelines, and requests consultation when navigating uncertain situations.

BASIC QUALIFICATIONS

• Bachelor’s degree

• 12+ years of commercial experience in the pharmaceutical industry, inclusive of adjacent industries (eg, consulting, CPG, financial services, academia)

• Expertise in global pharmaceutical/biotech

• Ability to work independently across senior level stakeholders and demonstrates judgement of what needs to be escalated

• Strong team player with demonstrated ability to engage experts from a wide range of functional areas to improve business performance and find a path forward

• Strong strategic thinking, analytical skills, detail and action oriented, creative, flexible, self-motivated

• Proven track record of translating key insights into meaningful strategies and tactics

• Excellent verbal and written communication skills for a wide range of audiences

• Solid understanding of today’s Global and US pharmaceutical environment, including Regulatory, Legal and Compliance

• Is a role model for the Pfizer Values

Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.

PREFERRED QUALIFICATIONS

• Advanced degree, ideally MBA, MPH, PhD, NP, MD, DO, etc

• Commercial strategy, launch, and lifecycle management experience

NON-STANDARD WORK SCHEDULE, TRAVEL OR ENVIRONMENT REQUIREMENTS

• Ability to travel approximately 20-25% of the time

Other Job Details:

Last day to apply: April 13, 2026

The annual base salary for this position ranges from $214,900.00 to $358,100.00. In addition, this position is eligible for participation in Pfizer’s Global Performance Plan with a bonus target of 22.5% of the base salary and eligibility to participate in our share based long term incentive program. We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives and to support each of life’s moments. Benefits offered include a 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution, paid vacation, holiday and personal days, paid caregiver/parental and medical leave, and health benefits to include medical, prescription drug, dental and vision coverage. Learn more at Pfizer Candidate Site – U.S. Benefits | (uscandidates.mypfizerbenefits.com). Pfizer compensation structures and benefit packages are aligned based on the location of hire. The United States salary range provided does not apply to Tampa, FL or any location outside of the United States.

Relocation assistance may be available based on business needs and/or eligibility.

Candidates must be authorized to be employed in the U.S. by any employer.

U.S. work visa sponsorship (such as TN, O-1, H-1B, etc.) is not available for this role now or in the future.

Sunshine Act

Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider’s name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.

EEO & Employment Eligibility

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer. This position requires permanent work authorization in the United States.

Pfizer endeavors to makewww.pfizer.com/careersaccessible to all users. If you would like to contact us regarding the accessibility of our website or need assistance completing the application process and/or interviewing, please emaildisabilityrecruitment@pfizer.com This is to be used solely for accommodation requests with respect to the accessibility of our website, online application process and/or interviewing. Requests for any other reason will not be returned.

Marketing and Market Research